HCPCS Level II code Q5111 designates administration of pegfilgrastim-cbqv (Udenyca), a 0.5 mg biosimilar of pegfilgrastim used to reduce febrile neutropenia risk in patients undergoing myelosuppressive chemotherapy. Nationally, this code matters because biosimilar granulocyte colony-stimulating factors are increasingly used to manage chemotherapy-induced neutropenia, affecting pharmacy and outpatient infusion billing, payer coverage policies, and oncology practice workflows. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn what the code represents clinically, the typical service setting for administration, and which major payers are relevant for coverage considerations. The publication summarizes common billing practices, typical sites of service, and the clinical context for pegfilgrastim biosimilar injections. Data not available in the input for payer-specific rates, taxonomies, ICD-10 pairings, and related codes will be noted separately. This overview provides a concise reference for billing staff, oncology clinicians, and policy analysts working with biosimilar supportive-care agents in outpatient settings.